by Tony Akiwumi | Nov 10, 2025 | Pharma / Market Access
A few years ago, I joined a cross-functional meeting for a major launch. There were at least twenty people in the room, each representing a different function. The chart projected on the wall looked like a spider web drawn by someone who’d given up halfway through....
by Tony Akiwumi | Nov 10, 2025 | Pharma / Market Access
Years ago, I released a small music single. I spent days obsessing over the sound, the mix, and the production. When it finally launched, I proudly handed it to friends — only to realise they cared less about the technical quality and more about how it made them feel....
by Tony Akiwumi | Nov 10, 2025 | Pharma / Market Access
Pharma loves a quick win. A fast HTA approval, a glowing headline, a big first-quarter number. But short-term victories can come at a long-term cost if they create mistrust, inequity, or pricing backlash. Take pricing. Launching at the highest possible level might...
by Tony Akiwumi | Nov 10, 2025 | Pharma / Market Access
Ask most pharma executives how a launch is going, and they’ll quote sales figures. Revenue is easy to measure and looks impressive on a slide. But it doesn’t tell the whole story. A drug can sell well while failing to reach those who need it most — or sell modestly...
by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
“Data-driven” sounds impressive. It makes strategy sound objective, scientific, and precise. However, being “data-driven” frequently masks another issue: people use numbers to justify their existing beliefs. Data doesn’t make decisions; people do. And when...
by Tony Akiwumi | Nov 8, 2025 | Pharma / Market Access
Stakeholder mapping often gets treated like homework. Teams create lists of regulators, payers, clinicians, and patient groups, tick a box, and move on. But done properly, it can shave months off timelines and save millions in opportunity cost. The most common mistake...
